

Cover Story
Free
This series re-examines the concurrent controversies at the Cancer Prevention and Research Institute of Texas and MD Anderson Cancer Center. This examination is possible in part because of new insight provided by Alfred Gilman, the Nobel laureate who served as the first scientific director of the state institution that distributes $300 million a year. Gilman died on Dec. 23, 2015.
In Brief


Drugs & Targets
Trending Stories
- Daraxonrasib’s success in treating pancreatic cancer is a reminder that clinical cancer researchers are heroes
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pam Bondi diagnosed with thyroid cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- Wafik El-Deiry steps down as director of Brown’s Legorreta Cancer Center











